{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:01:07Z","timestamp":1753891267795,"version":"3.41.2"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Traditional Chinese medicine has been used for Coronavirus disease 2019 (COVID-19) as a therapeutic option. Lianhuaqingwen capsules (LHQW) are well-recognized for their efficacy, while Kegan Liyan oral liquid (KGLY), widely used for influenza treatment, has emerged as a promising candidate for COVID-19 therapy. This trial aims to assess whether KGLY is non-inferior to LHQW in treating mild COVID-19.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A total of 127 participants (63 in KGLY group and 64 in LHQW group) were randomly allocated to receive either KGLY therapy or LHQW therapy in a 1:1 ratio. The treatment was given for 7\u202fdays, and the follow-up period was 3\u202fdays.<\/jats:p><\/jats:sec><jats:sec><jats:title>Outcome measures<\/jats:title><jats:p>The primary outcome was symptom remission at day 10. Secondary outcomes included symptom recovery, time to symptom remission, recovery rates and time to recovery of selected symptoms, change in visual analog scale score for selected symptoms, area under the curve of the visual analog scale score for sore throat, negative conversion of the SARS-CoV-2 infection, having a positive test result after negative conversion, and incidence of pneumonia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Full analysis set analysis showed that the symptom remission rate at day 10 was 60.7% with KGLY and 58.3% in LHQW (difference\u202f+\u202f2.3 p.p., lower limit of 95% confidence interval\u202f\u2212\u202f14.8 p.p.), indicating non-inferiority. There were no significant differences between the groups for any secondary outcome. The occurrence of adverse events did not differ between the groups and no severe adverse events were documented in either group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Based on the study results, this trial proved that KGLY was non-inferior to LHQW for mild COVID-19, providing a promising option for COVID-19 treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical trial registration<\/jats:title><jats:p><jats:ext-link>https:\/\/www.chictr.org.cn\/showproj.html?proj=166372<\/jats:ext-link>, Identifier, [ChiCTR2200059105].<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2025.1531370","type":"journal-article","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T05:14:27Z","timestamp":1740546867000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of Kegan Liyan oral liquid vs. Lianhuaqingwen capsules for patients with mild COVID-19: a double-blinded, randomized, controlled, non-inferiority trial"],"prefix":"10.3389","volume":"12","author":[{"given":"Yuewei","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yihe","family":"Chi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengting","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feiting","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongyang","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingmin","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaohan","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luoqi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaochun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruhong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Long","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuhua","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziyao","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingyu","family":"Quan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shangzhao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinying","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanbin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,26]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.7507\/1671-6205.202301036","article-title":"Symptom reported by hospital staff with mild COVID-19 during the omicron epidemic in Chongqing","volume":"22","author":"Feng","year":"2023","journal-title":"Chin J Respir Crit Care Med"},{"year":"","key":"ref2"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"107843","DOI":"10.1016\/j.pharmthera.2021.107843","article-title":"Traditional Chinese medicine (TCM) in the treatment of COVID-19 and other viral infections: efficacies and mechanisms","volume":"225","author":"Huang","year":"2021","journal-title":"Pharmacol Therapeut"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"153242","DOI":"10.1016\/j.phymed.2020.153242","article-title":"Efficacy and safety of Lianhuaqingwen capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: a multicenter, prospective, randomized controlled trial","volume":"85","author":"Hu","year":"2021","journal-title":"Phytomedicine"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1186\/s12985-023-02144-6","article-title":"Effects of Lianhuaqingwen capsules in adults with mild-to-moderate coronavirus disease 2019: an international, multicenter, double-blind, randomized controlled trial","volume":"20","author":"Zheng","year":"2023","journal-title":"Virol J"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"110641","DOI":"10.1016\/j.biopha.2020.110641","article-title":"Lianhua Qingwen prescription for coronavirus disease 2019 (COVID-19) treatment: advances and prospects","volume":"130","author":"Li","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"3763","DOI":"10.7501\/j.issn.0253-2670.2020.14.021","article-title":"Clinical efficacy of Lianhua Qingwen integrated with Western medicine on COVID-19 by Meta-analysis","volume":"51","author":"Wang","year":"2020","journal-title":"Chin Tradit Herb Drug"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"102754","DOI":"10.1016\/j.ctim.2021.102754","article-title":"A meta-analysis for Lianhua Qingwen on the treatment of coronavirus disease 2019 (COVID-19)","volume":"60","author":"Zhuang","year":"2021","journal-title":"Complement Ther Med"},{"year":"","key":"ref9"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"127","DOI":"10.13457\/j.cnki.jncm.2014.07.060","article-title":"Clinical observation on 60 cases of KeGan LiYan Oral liquid in the treatment of influenza (wind-heat offending the lungs)","volume":"46","author":"Li","year":"2014","journal-title":"New Chinese Med"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"5","DOI":"10.16040\/j.cnki.cn15-1101.2019.02.003","article-title":"Observation on the therapeutic effect of KeGan LiYan Oral liquid in the treatment of chronic pharyngitis in 100 cases","volume":"38","author":"Deng","year":"2019","journal-title":"Inner Mongolia J Tradit Chin Med"},{"key":"ref12","first-page":"10","article-title":"Clinical analysis of 180 cases of acute upper respiratory tract infection treated by Kegan Liyan Oral liquid","volume":"16","author":"Lin","year":"2019","journal-title":"Journal of North Pharmacy"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.13288\/j.11-2166\/r.2020.14.001","article-title":"Guangdong provincial Programme of traditional Chinese medicine treatment of coronavirus disease 2019 (pilot second edition)","volume":"61","author":"Lin","year":"2020","journal-title":"J Tradit Chin Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"294","DOI":"10.7661\/j.cjim.20220126.034","article-title":"Expert consensus on the use of proprietary Chinese medicines in the prevention and treatment of novel coronavirus pneumonia","volume":"42","year":"2022","journal-title":"Chin J Integr Tradit West Med"},{"year":"","key":"ref15"},{"year":"","key":"ref16"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"993","DOI":"10.15585\/mmwr.mm6930e1","article-title":"Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network - United States, march-June 2020","volume":"69","author":"Tenforde","year":"2020","journal-title":"MMWR-Morb Mortal Wkly Rep"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1093\/ofid\/ofaa509","article-title":"Postacute COVID-19: An overview and approach to classification","volume":"7","author":"Amenta","year":"2020","journal-title":"Open Forum Infect Di"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"105056","DOI":"10.1016\/j.phrs.2020.105056","article-title":"Chinese herbal medicine for coronavirus disease 2019: a systematic review and meta-analysis","volume":"160","author":"Xiong","year":"2020","journal-title":"Pharmacol Res"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.apsb.2020.06.002","article-title":"Bioactive natural compounds against human coronaviruses: a review and perspective","volume":"10","author":"Xian","year":"2020","journal-title":"Acta Pharm Sin B"},{"year":"","key":"ref21"},{"year":"","key":"ref22"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3389\/fphar.2021.609213","article-title":"Efficacy and safety of traditional Chinese medicine in coronavirus disease 2019 (COVID-19): a systematic review and Meta-analysis","volume":"12","author":"Wang","year":"2021","journal-title":"Front Pharmacol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3389\/fphar.2022.988237","article-title":"Efficacy and safety of chinese herbal medicine for treating mild or moderate COVID-19: a systematic review and meta-analysis of randomized controlled trials and observational studies","volume":"13","author":"Zhu","year":"2022","journal-title":"Front Pharmacol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"154136","DOI":"10.1016\/j.phymed.2022.154136","article-title":"Herbal medicine for COVID-19: An overview of systematic reviews and meta-analysis","volume":"102","author":"Ang","year":"2022","journal-title":"Phytomedicine"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"217","DOI":"10.7326\/0003-4819-155-4-201108160-00005","article-title":"Oseltamivir compared with the Chinese traditional therapy Maxingshigan-Yinqiaosan in the treatment of H1N1 influenza","volume":"155","author":"Wang","year":"2011","journal-title":"Ann Intern Med"},{"key":"ref27","first-page":"217","article-title":"Clinical observation on 110 cases of pediatric acute upper respiratory tract infections treated with YinQiao san and ShenJie san","volume":"2","author":"Yan","year":"2012","journal-title":"China J Pharm Econ"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"558","DOI":"10.13820\/j.cnki.gdyx.20225042","article-title":"Traditional Chinese medicine syndromes and treatment strategies in 1155 patients infected with the omicron (BA.5.1.3) variant in Hainan Province","volume":"44","author":"Hua","year":"2023","journal-title":"Guangdong Med J"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"664","DOI":"10.7661\/j.cjim.20230213.033","article-title":"Analysis of Chinese medicine syndrome characteristics in 322 patients infected with mild SARS CoV-2 omicron variant in Shanghai","volume":"43","author":"Zhang","year":"2023","journal-title":"Chin J Integr Tradit West Med"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.3969\/j.issn.1004-745X.2020.11.004","article-title":"Discussion on TCM diagnosis and treatment of COVID-19 based on the three toxin theory of Chinese medicine master Zhou Zhongying","volume":"29","author":"Chen","year":"2020","journal-title":"J Emerg Tradit Chin Med"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jep.2016.03.057","article-title":"Kegan Liyan oral liquid ameliorates lipopolysaccharide-induced acute lung injury through inhibition of TLR4-mediated NF-\u03baB signaling pathway and MMP-9 expression","volume":"186","author":"Zhang","year":"2016","journal-title":"J Ethnopharmacol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.3390\/ijms25042109","article-title":"Baicalin protects broilers against avian coronavirus infection via regulating respiratory tract microbiota and amino acid metabolism","volume":"25","author":"Feng","year":"2024","journal-title":"Int J Mol Sci"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"115629","DOI":"10.1016\/j.ejmech.2023.115629","article-title":"An overview of anti-SARS-CoV-2 and anti-inflammatory potential of baicalein and its metabolite baicalin: insights into molecular mechanisms","volume":"258","author":"Dinda","year":"2023","journal-title":"Eur J Med Chem"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"853496","DOI":"10.3389\/fphar.2022.853496","article-title":"Inspiration for COVID-19 treatment: network analysis and experimental validation of Baicalin for cytokine storm","volume":"13","author":"You","year":"2022","journal-title":"Front Pharmacol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"755796","DOI":"10.3389\/fphar.2021.755796","article-title":"An integrated analysis reveals Geniposide extracted from Gardenia jasminoides J.Ellis regulates calcium signaling pathway essential for influenza a virus replication","volume":"12","author":"Zhou","year":"2021","journal-title":"Front Pharmacol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"111359","DOI":"10.1016\/j.intimp.2023.111359","article-title":"Chlorogenic acid inhibits porcine deltacoronavirus release by targeting apoptosis","volume":"127","author":"Shi","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"153310","DOI":"10.1016\/j.phymed.2020.153310","article-title":"Caffeic acid derivatives (CAFDs) as inhibitors of SARS-CoV-2: CAFDs-based functional foods as a potential alternative approach to combat COVID-19","volume":"85","author":"Adem","year":"2021","journal-title":"Phytomedicine"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"349","DOI":"10.19378\/j.issn.1003-9783.2007.05.005","article-title":"An experimental study on Kegan Liyan Oral liquid for counteracting coronavirus","volume":"5","author":"Lin","year":"2007","journal-title":"Tradit Chin Drug Res Clin Pharmacol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"496","DOI":"10.19378\/j.issn.1003-9783.2010.05.015","article-title":"Experimental study of anti-influenza virus H9N2 effects of Kegan Liyan Oral liquid in vivo","volume":"20","author":"Li","year":"2010","journal-title":"Tradit Chin Drug Res Clin Pharmacol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1142\/s0192415x09007570","article-title":"Regulation of influenza virus-caused oxidative stress by Kegan Liyan Oral prescription, as monitored by Ascorbyl radical ESR signals","volume":"37","author":"Duan","year":"2009","journal-title":"Am J Chinese Med"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1531370\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T05:14:38Z","timestamp":1740546878000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1531370\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,26]]},"references-count":40,"alternative-id":["10.3389\/fmed.2025.1531370"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1531370","relation":{},"ISSN":["2296-858X"],"issn-type":[{"type":"electronic","value":"2296-858X"}],"subject":[],"published":{"date-parts":[[2025,2,26]]},"article-number":"1531370"}}